

Laboratory changes associated with medication non-adherence in patients with hypertension over six months of the COVID-19 pandemic

Short title: Medical non-adherence and laboratory changes in hypertensive patients

Shu-Mei Chang¹, Yi-Chun Chen², Chin-Feng Hsuan³, I-Cheng Lu^{4,*}, Hung-Yi Chuang⁵

¹Outpatient Department, E-DA Dachang Hospital

²Department of Health Management, I-Shou University

³Department of Cardiology, E-DA Hospital and College of Medicine, I-Shou University

⁴Department of Occupational Medicine, E-DA Hospital and College of Medicine, I-Shou University

⁵Department of Public Health, Kaohsiung Medical University, and Department of Environmental and Occupational Medicine, Kaohsiung Medical University Hospital

*Corresponding author

E-mail: ichenglu2@gmail.com (IL)

¶These authors contributed equally to this work.

&These authors also contributed equally to this work.

Abstract

The coexistence of multiple diseases is common in the elderly and often accompanied by medication non-adherence. This study investigated the relationship between medication non-adherence and laboratory findings inpatients with hypertension and hypertensive comorbidities (i.e., diabetes and nephropathy) in southern Taiwan during 6 months of the coronavirus disease pandemic. This was a panel study and involved outpatients from three hospitals classified as regional hospitals or above. Questionnaires were used to collect information on patient demographics, diet, medication adherence, and laboratory data at the time of recruitment and 6 months after. A total of 140 patients with only hypertension and 98 patients with hypertension and comorbidities were recruited, and the changes in blood pressure and laboratory data were assessed after 6 months. Analyses performed with generalized estimating equations showed that patients who had not forgotten to take medication had a higher estimated glomerular filtration rate. Moreover, patients who did not change their medication time arbitrarily had lower low-density lipoprotein levels. Furthermore, patients who did not stop or interrupt their medication arbitrarily had lower diastolic blood pressures and low-density lipoprotein levels. Overall, patients with better medication adherence had better estimated glomerular filtration rates, lower low-density lipoprotein levels, and lower diastolic blood pressures.

Keywords: hypertension, adherence, multiple disease comorbidities

Introduction

The present study was conducted in 2020, during the coronavirus disease (COVID-19) pandemic, when most people avoided going to public places and even visits to hospitals were reduced. A study in Malaysia showed that patients with hypertension were more likely to be negatively affected by the pandemic [1]. According to the results of the National Nutrition and Health Survey conducted from 2017–2020, approximately 5.23 million people above the age of 20 had hypertension, accounting for about a quarter of the population of Taiwan [2].

Hypertension is the main risk factor for many global illnesses and premature death, and its burden of disease has exceeded that of smoking and overweight [3]. Hypertension is also a common risk factor for major chronic diseases such as cardiovascular disease, stroke, diabetes, and nephropathy. In 2010, high blood pressure was the leading cause of death and disability-adjusted life years worldwide [4]. Moreover, in 2017, the American Heart Association reduced blood pressure threshold values for hypertension to promote earlier control of comorbidities and reduce the incidence of stroke and cardiovascular disease [4]. Hypertension is an important global health challenge and a leading preventable risk factor for premature death and disability worldwide [5].

Most patients with hypertension require more than two different kinds of anti-hypertensive drugs to maintain their blood pressure within the ideal range (below 140/90 mmHg) as well as to reduce the incidence of comorbidities, such as cardiovascular disease, cerebrovascular disease, diabetes, chronic kidney disease, and retinopathy [6,7].

In current clinical hypertension management practices, the main obstacles in managing patients with hypertension are comorbidity management and poor medication adherence, which may be explained by a lack of persistence [8]. The World Health Organization has recently highlighted increased adherence as a key developmental need in reducing cardiovascular disease

[5], and researching new, effective medications is required to better control hypertension in patients. However, in the absence of new, effective anti-hypertensive medications, improving medication adherence of readily available therapies is important and has been emphasized by recent guidelines [9]. Approximately half of patients with uncontrolled hypertension do not take their medication correctly [10]. In the 2015 US National Health Interview Survey, 23.8 million adults with hypertension reported an overall weighted non-adherence rate of 31.0% [11]. Similarly, an analysis of data from Taiwan's National Health Insurance Research Database in 2010 revealed that up to 85.5% of patients with poor disease control are non-adherent to treatment [12].

Furthermore, according to Schiffrin et al. [13], the most common comorbidities in patients with coronavirus disease (COVID-19) and acute respiratory distress syndrome were hypertension (27%), diabetes (19%), and cardiovascular disease (6%). Although there have not yet been severe COVID-19 outbreaks in Taiwan, patients with hypertension and hypertensive comorbidities are still inevitably involved in behaviors that include medication non-adherence. Therefore, the purpose of this study was to investigate the changes in laboratory data and medication non-adherence among patients with hypertension and hypertensive comorbidities (i.e., diabetes and nephropathy). By doing this, we hoped to understand whether the pandemic impacted patients' willingness to visit doctors and take medications. The findings may serve as a guide for better patient adherence as well as treatment adjustments and enhanced patient education by clinical physicians.

Materials and Methods

Patient Recruitment

A panel study was conducted between January 2020 and June 2021. During the 6-month study period, the COVID-19 pandemic was ongoing and patient visits to hospitals had reduced. We recruited outpatients with hypertension and hypertensive comorbidities, such as diabetes or nephropathy, in three hospitals classified as regional hospitals or above. The patients were recruited into two groups: those with hypertension requiring medication (n=140) and those with hypertension and other comorbidities (i.e., diabetes or nephropathy) (n=98).

The study plan was reviewed and approved by the Research Ethics Committee (IRB: EMRP108065). This study complied with research ethics regulations and the principle of informed consent. The consent form was presented to the subjects in a quiet room, the contents of the consent form were explained, and questions regarding the study were answered in a way that the subjects could understand. We confirmed that the subjects understood the contents of the research and gave them sufficient time to consider and communicate. Finally, when the subjects agreed to participate in the study, they signed the consent form. The study was explained to the patients who met the inclusion criteria during their visit to their doctors, after which, those who agreed signed the consent form and completed the questionnaire anonymously in a quiet and empty room.

Inclusion Criteria

Outpatients who were at least 40 years old and had been diagnosed with hypertension by a physician at least 1 year prior were included in the study. Moreover, the ability to take drugs alone; clear consciousness; the ability to communicate with the interviewer in the Mandarin, Taiwanese, or Hakka languages; and the ability to understand verbal questions were also inclusion criteria. Patients with a terminal-stage disease with a life-expectancy of 6 months or less, or other special circumstances, such as aggressiveness, were excluded.

Questionnaires and Interviews

The questionnaire was specifically tailored to meet the purpose of this study and was based on references from both domestic and foreign literature [14]. Several revisions were made according to expert discussions, and the draft was finalized after a preliminary trial. The questionnaire had seven parts: (1) basic information, including sex, age, religion, marital status, living conditions, body weight, and height; (2) medication status, including the number of pills taken, medication frequency, regularity in taking medications, and presence/absence of side effects; (3) medication non-adherence behavior was recorded, including forgetting to take medication more than two times in a week within the past 3 months, after which they were divided into groups that included forgetting to take medication, changing the medication time arbitrarily, stopping or interrupting the medication arbitrarily, reducing the medication times arbitrarily, decreasing the dosage arbitrarily, and purchasing medications not prescribed by physicians arbitrarily [14]; (4) follow-up visits, including whether or not the patient came for follow-ups regularly; (5) lifestyle, such as drinking, smoking, coffee consumption, exercise, sleep, dietary supplements, and tea consumption habits; (6) past medical history and self-assessed health status; and (7) diet, including types of diet [15].

Blood pressure measurement and laboratory investigations

Blood pressures (systolic and diastolic values), glycated hemoglobin (HbA1c), fasting blood glucose (FBS), creatinine, the urine protein/urine creatinine ratio, estimated glomerular filtration rate (eGFR), and low-density lipoprotein levels (LDL) were measured initially and during patient follow-ups 3 to 6 months after, upon orders from the clinical physician.

Laboratory investigations were performed in the same laboratory to avoid bias.

Data Analysis

Descriptive statistics was used to analyze the distribution of demographic variable data. Categorical variables were presented in frequency tables and expressed as percentages. Continuous variables were expressed as average values with standard deviations. The chi-square (χ^2) and Fisher's exact tests were used to compare two categorical variable groups. Two-tailed independent sample t-tests and paired sample t-tests were used to compare two continuous variable groups. Three continuous variable groups were compared using a one-way analysis of variance (ANOVA). This study used generalized estimating equations (GEEs) to find the association between medication non-adherence behaviors and laboratory data adjusted interference factors (sex, age, education, and marital status), and data from the same participants were analyzed multiple times. SPSS18.0 statistical software was used for data analysis, and α was set at 0.05.

Results

A total of 238 patients were recruited: 140 with only hypertension, 59 with hypertension and diabetes, and 39 with hypertension and nephropathy. There were no significant differences in age, body mass index, sex, marital status, occupation, and living condition between the three groups. Regarding education, there were 35 (25.0%) only hypertension patients that had college degrees, 15 (25.4%) hypertension and diabetes patients with college degrees, and 18 (47.4%) hypertension and nephropathy patients with college degrees. The proportion of people with college degrees with hypertension and nephropathy was significantly higher than the proportion of people with college degrees in the other two groups ($P=0.016$) (Table 1).

Table 1. Demography of patients with only hypertension, with hypertension and diabetes, and with hypertension and nephropathy (n=238)

Variables	Only Hypertension (%)	Hypertension and Diabetes (%)	Hypertension and Nephropathy (%)	n	p-value
Age, years M(SD) ^b	61.8(11.1)	64.2(8.9)	60.9(12.7)	238	0.376
BMI^a, kg/m² M(SD) ^b	26.7 (4.15)	27.5(4.36)	26.4(4.63)	238	0.262
Sex					
Male	77 (55.0%)	32 (54.2%)	21 (53.8%)	130	0.996

Female	63 (45.0%)	27 (45.8%)	18 (46.2%)	108	
Marital status					
Married	103 (74.1%)	45 (76.30%)	27 (69.2%)	174	0.816
Single	27 (19.4%)	10 (16.9%)	11 (28.2%)	48	
Divorced	6 (4.3%)	3 (5.1%)	1 (2.6%)	10	
Widowed	3 (2.2%)	1 (1.7%)	0 (0.0%)	4	
Religion					
Taoism	82 (61.7%)	26 (44.8%)	17 (48.6%)	125	0.062
Buddhism	36 (27.1%)	27 (46.6%)	9 (25.7%)	72	
Christian	7 (5.3%)	3 (5.2%)	4 (11.4%)	14	
Catholic	1 (0.8%)	0 (0.0%)	0 (0.0%)	1	
Others	7 (5.3%)	2 (3.4%)	5 (14.3%)	14	
Education					
Junior Highschool	50 (35.7%)	29 (49.2%)	8 (21.1%)	87	0.016
Senior/Vocational highschool	44 (31.4%)	12 (20.3%)	12 (31.6%)	68	
College	35 (25.0%)	15 (25.4%)	18 (47.4%)	68	
Master	11 (7.9%)	3 (5.1%)	0 (0.0%)	14	
Occupation					
Employed	49 (35.0%)	20 (33.9%)	12 (30.8%)	81	0.885
Unemployed	91 (65.0%)	39 (66.1%)	27 (69.2%)	157	
Living					

Condition					
Lives Alone	10 (7.1%)	4 (6.9%)	5 (12.8%)	19	0.154
Lives with Family	130 (92.9%)	54 (93.1%)	33 (84.6%)	217	

^aBody mass index

^bMean (standard deviation)

Patients were divided into different medication non-adherence behavior groups. Among the patients who did not return after 6 months, 4 (2.9%) had only hypertension, 3 (5.1%) had hypertension and diabetes, and none (0.0%) had hypertension and nephropathy. The difference among the groups was not significant ($P=0.344$)(Table 2).

Table 2. Medication non-adherence behavior and loss to follow-up among patients with only hypertension, with hypertension and diabetes, and with hypertension and nephropathy (n=238)

	Only Hypertension	Hypertension and Diabetes	Hypertension and Nephropathy	n	p-value
Forgot to take medication					
Yes	46 (32.9%)	12 (20.3%)	10 (25.6%)	68	0.184
No	94 (67.1%)	47 (79.7%)	29 (74.4%)	170	

Changed medication time arbitrarily					
Yes	24 (17.1%)	5 (8.5%)	7 (18.4%)	36	0.248
No	116 (82.9%)	54 (91.5%)	31 (81.6%)	201	
Stopped or interrupted medication arbitrarily					
Yes	16 (11.4%)	3 (5.1%)	3 (7.7%)	22	0.346
No	124 (88.6%)	56 (94.9%)	36 (92.3%)	216	
Reduced the medication times arbitrarily					
Yes	9 (6.4%)	1 (1.7%)	2 (5.3%)	12	0.379
No	131 (93.6%)	58 (98.3%)	36 (94.7%)	225	
Decreased the dosage arbitrarily					
Yes	8 (5.8%)	9 (15.3%)	4 (10.3%)	21	0.097

No	130 (94.2%)	50 (84.7%)	35 (89.7%)	215	
Returned after six months					
No	4 (2.9%)	3 (5.1%)	0 (0.0%)	7	0.344
Yes	136 (97.1%)	56 (94.9%)	39 (100.0%)	231	

The patients were followed for 6months, and blood laboratory data were analyzed using a one-way ANOVA. The average HbA1c of patients with hypertension and diabetes was 6.9 (1.65), which was significantly higher than that of the other two groups ($P=0.006$). The average creatinine level in patients with hypertension and nephropathy was 2.4 (3.27), which was significantly higher than that of the other two groups ($P<0.000$). The estimated glomerular filtration rate (eGFR) of patients with hypertension and nephropathy was 59.7 (34.6), which was significantly lower than that of the other two groups($P<0.001$) (Table 3).

Table 3. Laboratory data of patients with only hypertension, with hypertension and diabetes, and with hypertension and nephropathy

Variables	Only Hypertension	Hypertension and Diabetes	Hypertension and Nephropathy	n	p-value
Systolic Blood Pressure,	143.0 (19.5)	148.3 (19.3)	141.3 (16.2)	194	0.192

mmHg					
M (SD)^a					
Diastolic	82.5 (12.3)	85.2 (11.8)	80.7 (10.8)	192	0.231
Blood					
Pressure,					
mmHg					
M (SD)^a					
HbA1C^b,					
%					
M (SD)^a	6.28 (0.94)	6.9 (1.65)	6.11 (0.93)	153	0.006
FBS^c,					
mg/dL					
M (SD)^a	109.4 (38.9)	127.5 (48.5)	118.3 (57.8)	190	0.067
Creatinine,					
μmol/L					
M (SD)^a	1.14 (1.14)	0.93 (0.30)	2.4 (3.27)	195	<0.001
eGFR^d,					
mL/min					
M (SD)^a	80.6 (29.7)	82.0 (25.6)	59.7 (34.6)	196	0.001
LDL^e,					
mg/dL					
M (SD)^a	105.6 (32.5)	99.5 (32.4)	97.8 (32.5)	189	0.350

^aMean (standard deviation)

^bGlycated hemoglobin

^cFasting blood sugar level

^dEstimated glomerular filtration rate

^eLow-density lipoprotein

After monitoring the changes in blood pressure and laboratory data for 6 months, GEEs were applied according to the non-adherence items collected at the time of the questionnaire, and factors including sex, age, education, marital status were controlled. The eGFR and LDL could be evaluated using parameters of whether or not the patient had forgotten to take medication. The estimated β value was 9.887, and the P value was 0.024, indicating that eGFR increased in patients who had not forgotten to take medication. With the estimated β value of -13.34 and P value of 0.014, LDL levels decreased in patients who did not change their medication time arbitrarily. Moreover, diastolic blood pressures and LDL levels could be evaluated using parameters of whether the patients had stopped or interrupted their medication. The estimated β value was -7.046, and the P value was 0.005, indicating that patients who did not stop or interrupt their medication arbitrarily had lower diastolic blood pressures. Similarly, with an estimated β value of -19.80 and P value of 0.006, patients who did not stop or interrupt their medication arbitrarily had lower LDL levels.

Discussion

In the three groups of patients (only hypertension, with hypertension and diabetes, and with hypertension and nephropathy), the proportion of college degrees in the group with hypertension and nephropathy was significantly higher than that of the other two groups. The overall rate of loss to follow-up after 6 months in the three groups was 2.94%. However, the group with hypertension and nephropathy had a return rate of 100%, which may be related to the higher education level of this group. Among older patients with hypertension who have a low level of education and no social support, there is a need for tailored education to better understand and adhere to medication [16]. Therefore, health education should be increased for patients with only hypertension and patients with hypertension and diabetes to facilitate the control of chronic diseases.

Among patients who changed their medication time and who stopped or interrupted their medication arbitrarily, the group with only hypertension had higher rates of medication non-adherence behavior, which may indicate a lack of insight to the disease. Therefore, health education about medication adherence for this group should be increased to avoid future comorbidities. However, adherence increases with the number of chronic diseases, while sex, age, and number of drugs do not show a consistent effect [17].

Although this study did not find significant differences in medication non-adherence behavior and return rates after 6 months among the three groups, the proportion of patients who forgot to take medication was highest in the group with only hypertension. The rate of stopping or interrupting one's medication arbitrarily as well as average LDL levels in this group were also higher than that in the other two groups. Therefore, increased risk of cardiovascular disease should be monitored. The group with hypertension and diabetes had lower rates of medication

time change and arbitrary reduction of medication times when compared to the other groups.

This group, however, had the highest rate of arbitrary decrease of dosage and the highest average blood pressure among the three groups, indicating that clinical healthcare professionals may have to strengthen the health literacy level and promote adherence to the prescribed dosage in patients with hypertension and diabetes. Emphasis should be placed on accurately measuring and recording blood pressure to effectively control these patients' blood pressures and blood sugar levels.

According to the GEEs to examine changes after 6 months, if the rate of forgetting medication was reduced, the eGFR of the hypertensive group could be increased by approximately 9.887 mL/min ($P=0.024$). Moreover, if the rate of changing medication time arbitrarily was reduced, the LDL level of patients with hypertension could be reduced by approximately 13.340 mg/dL ($P=0.014$). Finally, the analysis showed that if the rate of stopping or interrupting medication arbitrarily was reduced, the LDL level of the group with hypertension could be reduced by up to 19.801 mg/dL ($P=0.006$), and the diastolic blood pressure could be reduced by approximately 7.046 mmHg ($P=0.005$).

Medication non-adherence is a major barrier to treatment and a key obstacle in improving patient prognosis. Persistent adherence is a complex phenomenon, and no single intervention can solve this challenge. The ability of patients to optimally follow treatment plans is frequently compromised by more than one barrier, including social and economic factors, the health care team and system, disease characteristics, disease therapies, and other patient-related factors [18]. For example, patients with merchant occupations, physical inactivity, and diabetes mellitus comorbidity were significantly associated with higher rates of medication non-adherence [19].

Solving the problems related to each of these factors is necessary if adherence to therapies is to be improved.

Research has shown that multidisciplinary team-based care can effectively improve the approach to hypertension control by offering patient-centered treatment, which is associated with better adherence [21,22] and a greater influence on the health of patients with hypertension. This may be provided through adequate education on the use of medicine from pharmacists to improve adherence. A literature review showed that predictors of adherence included trust, communication, and empathy; efforts to improve patients' understanding of medication benefits; and access and trust in their provider and health system. Improving providers' recognition and understanding of patients' beliefs, fears, and values, as well as their own biases is also necessary to achieve increased medication adherence and improved population health [23]. In Taiwan, clinical physicians usually adjust medications and educate patients with hypertension and hypertensive comorbidities according to changes in laboratory findings and blood pressure measurements at the patients' house or hospital. Furthermore, a study in Japan revealed that higher medication regimen complexity had a higher non-adherence [20]. Using double-combination or triple-combination therapies may be helpful in reducing the treatment dosage and improving medication adherence.

This study had some limitations. First, this was a pilot study conducted at outpatient departments during the COVID-19 pandemic, even though the severity and rate of complications were not high. Second, the decrease in patient visits to the outpatient department due to the COVID-19 pandemic made it difficult to follow up with the patients. We intend to continue data collection and analysis to examine more interesting findings.

Conclusion

This study was conducted during the COVID-19 pandemic. Analyses performed with generalized estimating equations showed that patients who had not forgotten to take medications had a higher eGFR, and patients who did not change their medication time arbitrarily had lower LDL levels. Moreover, patients who did not stop or interrupt their medication arbitrarily had lower diastolic blood pressures and LDL levels. The results of this study may provide more insight on the relationship between medication non-adherence and changes in laboratory data, which may be helpful in adjusting medicines and enhancing patient education by clinical physicians.

Acknowledgments

Thanks for our part time worker, Liang-Yu Chen, and the nurse, Yin-Jin Lin, and a lot of people who joined in this study.

References

1. ElnaemMH, Kamarudin NH, Syed NK, HuriHZ, DeheleIS, Cheema E. Associations between socio-demographic factors and hypertension management during the COVID-19 pandemic: preliminary findings from Malaysia. *Int J Environ Res Public Health*. 2021;18:9306. doi: 10.3390/ijerph18179306.
2. Ministry of Health and Welfare National Health Service. National Health Service Annual Report. 2017. Available from: <https://www.hpa.gov.tw/Pages/List.aspx?nodeid=1248>
3. GuptaP, Patel P, Štrauch B, Lai FY, Akbarov A, MarešováV, et al. Risk factors for nonadherence to antihypertensive treatment. *Hypertension*. 2017;69: 1113-1120. doi:10.1161/hypertensionaha.116.08729.
4. The American College of Cardiology/American Heart Association. 2017 high blood pressure clinical practice guideline. Retrieved from <https://www.ahajournals.org/hyp/guidelines2017>
<https://doi.org/10.1161/HYP.0000000000000006>
5. CimmarutaD, Lombardi N, Borghi C, RosanoG, Rossi F, MugelliA. Polypill, hypertension and medication adherence: The solution strategy? *Int J Cardiol*. 2018;252: 181-186. doi: 10.1016/j.ijcard.2017.11.075.
6. James PA, Oparil S, Carter BL, CushmanWC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311: 507-520. doi: 10.1001/jama.2013.284427.
7. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The task force for the management

- of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013;31: 1281-1357.doi:10.1093/eurheartj/eh151.
8. Burnier M. Drug adherence in hypertension. *Pharmacol Res*. 2017;125: 142-149. doi: 10.1016/j.phrs.2017.08.015.
9. Burnier M, Egan BM. Adherence in hypertension. *Circ Res*. 2019;124: 1124-1140.doi: 10.1161/circresaha.118.313220.
10. Carvalho AS, Santos P. Medication adherence in patients with arterial hypertension: The relationship with healthcare systems' organizational factors. *Patient Prefer Adherence*. 2019;13:1761-1774. doi:10.2147/ppa.S216091.
11. Chang TE, Ritchey MD, Park S, Chang A, Odom EC, Durthaler J, et al. National rates of nonadherence to antihypertensive medications among insured adults with hypertension. *Hypertension*. 2019;74: 1324-1332. doi:10.1161/hypertensionaha.119.13616.
12. Wu PH, Yang CY, Yao ZL, Lin WZ, Wu LW, Chang CC. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. *Am J Hypertens*. 2010;23: 150-160.doi:10.1038/ajh.2009.210.
13. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. *Am J Hypertens*. 2020;33: 373-374. doi: 10.1093/ajh/hpaa057.
14. Chang SM, Lu IC, Chen YC, Hsuan CF, Lin YJ, Chuang HY. Behavioral factors associated with medication nonadherence in patients with hypertension. *Int J Environ Res Public Health*. 2021;18: 1-10. doi: 10.3390/ijerph18189614.
15. Ho CP, Yu JH, Liu TY, Lee JFT. Factors involved in the medication adherence of hypertensive patients. *J Nurs Healthc Res*. 2015;11: 23-32.doi:10.6225/JNHR.11.1.23.

16. GuoSE,Hong RM, Hwang SL, Chi MC, Chou CT, Lin YC, et al.Medication adherence among patients with chronic obstructive pulmonary disease in Chia-Nan area of Taiwan. FJMM. 2015;14: 9-20.doi: 10.3966/181020932016031401002.
17. Uchmanowicz B,Chudiak A, Uchmanowicz I,Rosińczuk J, Froelicher ES.Factors influencing adherence to treatment in older adults with hypertension.ClinInterv Aging. 2018;13: 2425-2441. doi: 10.2147/cia.S182881.
18. MorenoJA, Gimeno MA, Poblador PB, GonzálezRF, Aza PS MM, Menditto E, et al.Adherence to treatment of hypertension, hypercholesterolaemia and diabetes in an elderly population of a Spanish cohort.Med Clin (Barc). 2019;153: 1-5. doi: 10.1016/j.medcli.2018.10.023.
19. KebedeSimegn B, Chelkeba L, Dessie Alamirew B. Clinicians' prescribing pattern, rate of patients' medication adherence and its determinants among adult hypertensive patients at Jimma University Medical Center: Prospective cohort study. PLoS One. 2021;16(4):e0249222. doi: 10.1371/journal.pone.0249222.
20. Wakai E, Ikemura K, Kato C, Okuda M. Effect of number of medications and complexity of regimens on medication adherence and blood pressure management in hospitalized patients with hypertension. PLoS One. 2021;16(6):e0252944. doi: 10.1371/journal.pone.0252944.
21. World Health Organization.2003. <https://doi.org/10.5144/0256-4947.2004.221>
22. Proia KK, Thota AB, Njie GJ, Finnie RK, Hopkins DP, Mukhtar Q, et al.Team-based care and improved blood pressure control: a community guide systematic review.Am J Prev Med. 2014;47:86-99. doi: 10.1016/j.amepre.2014.03.004.

23. Lauffenburger JC, Shrank WH, Bitton A, Franklin JM, Glynn RJ, Krumme AA, et al. Association between patient-centered medical homes and adherence to chronic disease medications: a cohort study. *Ann Intern Med*. 2017;166: 81-88. doi: 10.7326/m15-2659.
24. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. *Am J Med Sci*. 2016;351: 387-399. doi: 10.1016/j.amjms.2016.01.010.
25. Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The effect of self-monitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. *Am J Hypertens*. 2015;10: 1209-1221. doi: 10.1093/ajh/hpv008.